Search Results - "Perez‐Garcia, Luis"

Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial by Giorgino, Francesco, Yu, Maria, Haupt, Axel, Milicevic, Zvonko, García‐Pérez, Luis‐Emilio

“…The long‐acting glucagon‐like peptide‐1 receptor agonist dulaglutide acts by stimulating insulin secretion and reducing glucagon levels in a glucose‐dependent…”
Get full text

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial by Ludvik, Bernhard, Frías, Juan P, Tinahones, Francisco J, Wainstein, Julio, Jiang, Honghua, Robertson, Kenneth E, García-Pérez, Luis-Emilio, Woodward, D Bradley, Milicevic, Zvonko

“…Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce bodyweight in…”
Get full text

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months by Boye, Kristina S., Lebrec, Jérémie, Dib, Anne, Heitmann, Elke, Federici, Marco Orsini, Yu, Maria, Sapin, Hélène, Barrett, Annabel, Guerci, Bruno, Giorgino, Francesco, Füchtenbusch, Martin, García‐Pérez, Luis‐Emilio

“…AimTo report health‐related patient‐reported outcomes (PROs) in people with type 2 diabetes (T2D) initiating their first injectable glucose‐lowering medication…”
Get full text

Adherence to Therapies in Patients with Type 2 Diabetes by García-Pérez, Luis-Emilio, Álvarez, María, Dilla, Tatiana, Gil-Guillén, Vicente, Orozco-Beltrán, Domingo

“…Adherence to therapy is defined as the extent to which a person’s behavior in taking medication, following a diet, and/or executing lifestyle changes,…”
Get full text

The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes ( TROPHIES ): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes by Giorgino, Francesco, Guerci, Bruno, Füchtenbusch, Martin, Lebrec, Jérémie, Boye, Kristina, Orsini Federici, Marco, Heitmann, Elke, Dib, Anne, Yu, Maria, Sapin, Hélène, García‐Pérez, Luis‐Emilio

“…AimsTo present the final results of the TROPHIES study (The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in…”
Get full text

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial by Cukierman-Yaffe, Tali, Gerstein, Hertzel C, Colhoun, Helen M, Diaz, Rafael, García-Pérez, Luis-Emilio, Lakshmanan, Mark, Bethel, Angelyn, Xavier, Denis, Probstfield, Jeffrey, Riddle, Matthew C, Rydén, Lars, Atisso, Charles Messan, Hall, Stephanie, Rao-Melacini, Purnima, Basile, Jan, Cushman, William C, Franek, Edward, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A, Lopez-Jaramillo, Patricio, Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J, Shaw, Jonathan E, Sheu, Wayne H-H, Temelkova-Kurktschiev, Theodora

“…Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor…”
Get full text

Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials by Jódar, Esteban, Romera, Irene, Wang, Qianqian, Roche, Sarah Louise, García‐Pérez, Luis‐Emilio

“…Aim To investigate the association between treatment with dulaglutide and glycaemic variability (GV) in adult patients with type 2 diabetes mellitus (T2D)…”
Get full text

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months by Guerci, Bruno, Giorgino, Francesco, Sapin, Hélène, Boye, Kristina, Lebrec, Jérémie, Federici, Marco Orsini, Heitmann, Elke, Dib, Anne, Füchtenbusch, Martin, García‐Pérez, Luis‐Emilio

“…Aims The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant…”
Get full text

Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c by Gallwitz, Baptist, Dagogo‐Jack, Samuel, Thieu, Vivian, Garcia‐Perez, Luis‐Emilio, Pavo, Imre, Yu, Maria, Robertson, Kenneth E., Zhang, Nan, Giorgino, Francesco

“…Aims To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in patients with type 2 diabetes by subgroups of gender, duration of diabetes and…”
Get full text

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER) by Matza, Louis S., Boye, Kristina S., Stewart, Katie D., Coyne, Karin S., Wullenweber, Paula K., Cutts, Katelyn N., Jordan, Jessica B., Wang, Qianqian, Yu, Maria, Currie, Brooke M., Malley, Karen G., Ishak, K. Jack, Hietpas, Ryan T., García‐Pérez, Luis‐Emilio

“…Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that…”
Get full text

Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States by Boye, Kristina S., Riddle, Matthew C., Gerstein, Hertzel C., Mody, Reema, Garcia‐Perez, Luis‐Emilio, Karanikas, Chrisanthi A., Lage, Maureen J., Riesmeyer, Jeffrey S., Lakshmanan, Mark C.

“…Aim To examine the generalizability of results from glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) cardiovascular outcome trials (CVOTs) in the US type 2…”
Get full text

Dengue and COVID‐19, overlapping epidemics? An analysis from Colombia by Cardona‐Ospina, Jaime A., Arteaga‐Livias, Kovy, Villamil‐Gómez, Wilmer E., Pérez‐Díaz, Carlos E., Katterine Bonilla‐Aldana, D., Mondragon‐Cardona, Álvaro, Solarte‐Portilla, Marco, Martinez, Ernesto, Millan‐Oñate, Jose, López‐Medina, Eduardo, López, Pio, Navarro, Juan‐Carlos, Perez‐Garcia, Luis, Mogollon‐Rodriguez, Euler, Rodríguez‐Morales, Alfonso J., Paniz‐Mondolfi, Alberto

“…Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has rapidly spread throughout Latin America, a…”
Get full text

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes by Matza, Louis S., Cutts, Katelyn N., Stewart, Katie D., Norrbacka, Kirsi, García-Pérez, Luis-Emilio, Boye, Kristina S.

“…Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined…”
Get full text

Ataxia telangiectasia mutated (ATM) modulates long interspersed element-1 (L1) retrotransposition in human neural stem cells by Coufal, Nicole G, Garcia-Perez, Josè Luis, Peng, Grace E, Marchetto, Maria C. N, Muotri, Alysson R, Mu, Yangling, Carson, Christian T, Macia, Angela, Moran, John V, Gage, Fred H

“…Long interspersed element-1 (L1) retrotransposons compose ∼20% of the mammalian genome, and ongoing L1 retrotransposition events can impact genetic diversity…”
Get full text

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison by Roux, Carel W., Hankosky, Emily R., Wang, Duzhe, Malik, Raleigh, Yu, Maria, Hickey, Ana, Kan, Hong, Bunck, Mathijs C., Stefanski, Adam, Garcia‐Perez, Luis‐Emilio, Wharton, Sean

“…Aim To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Materials and Methods Using SURMOUNT‐1…”
Get full text

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme by Mathieu, Chantal, Del Prato, Stefano, Botros, Fady T., Thieu, Vivian T., Pavo, Imre, Jia, Nan, Haupt, Axel, Karanikas, Chrisanthi A., García‐Pérez, Luis‐Emilio

“…Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion…”
Get full text

Dynamics of a Quantum Common-Pool Resource Game with Homogeneous Players' Expectations by Grau-Climent, Juan, García-Pérez, Luis, Alonso-Sanz, Ramon, Losada, Juan Carlos

“…In this work, we analyse a common-pool resource game with homogeneous players (both have boundedly rational expectations) and entanglement between players'…”
Get full text

LINE-1 Elements in Structural Variation and Disease by Beck, Christine R, Garcia-Perez, José Luis, Badge, Richard M, Moran, John V

“…The completion of the human genome reference sequence ushered in a new era for the study and discovery of human transposable elements. It now is undeniable…”
Get full text

The combined use of PSInSAR and UAV photogrammetry techniques for the analysis of the kinematics of a coastal landslide affecting an urban area (SE Spain) by Mateos, Rosa María, Azañón, Jose M., Roldán, Francisco J., Notti, Davide, Pérez-Peña, Vicente, Galve, Jorge P., Pérez-García, Jose Luis, Colomo, Carlos M., Gómez-López, Jose M., Montserrat, Oriol, Devantèry, Nùria, Lamas-Fernández, Francisco, Fernández-Chacón, Francisca

“…In the present work, the case of the Cármenes del Mar resort (Granada, Spain) is shown. It can be considered one of the most extreme examples on the…”
Get full text

Remitting neuropsychiatric symptoms in COVID‐19 patients: Viral cause or drug effect? by Forero‐Peña, David A., Hernandez, Matthew M., Mozo Herrera, Iriana Paola, Collado Espinal, Iván Bolívar, Páez Paz, Joselyn, Ferro, Carlos, Flora‐Noda, David M., Maricuto, Andrea L., Velásquez, Viledy L., Camejo‐Avila, Natasha A., Sordillo, Emilia M., Delgado‐Noguera, Lourdes A., Perez‐Garcia, Luis A., Morantes Rodríguez, Carlos G., Landaeta, María Eugenia, Paniz‐Mondolfi, Alberto E.

“…Numerous reports of neuropsychiatric symptoms highlighted the pathologic potential of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its…”
Get full text